Our study highlights a new opportunity for future drug development using SCFAs as an adjunct therapy to ameliorate non-resolving pneumonia by maintaining IL-10 expression and reducing expression of pro-inflammatory cytokines like TNF. This evidence concerns the gene IL10 and pneumonia.